Liver cirrhosis, liver cancer, etc
Conditions
Interventions
Suldaparilla sodium group:Suldaparilla sodium is subcutaneously injected once, one vial per day
Low molecular weight heparin group:Low molecular weight heparin is subcutaneously injected once, one vial per day
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age > 18 and < 70 years old, gender not limited; 2. Liver transplant recipients with high-risk factors for thrombotic events; 3. Patients without deep vein thrombosis or pulmonary embolism before the operation.
Exclusion criteria
Exclusion criteria: 1. Anticoagulant drugs were used for treatment before enrollment; 2. Patients with hereditary coagulation dysfunction; 3. Contraindications for the use of low-molecular-weight heparin/suldaparinol sodium: patients with severe organ bleeding (such as obvious abdominal hemorrhage or cerebrovascular accident, etc.), hemorrhagic diseases or bleeding tendency, and those allergic to low-molecular-weight heparin/suldaparinol sodium, etc., who are determined by a surgeon to be unable to use anticoagulation; 4. Patients with severe renal insufficiency; 5. The researchers believe that the current condition of the subjects is not suitable for participating in this study.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| The incidence of postoperative bleeding; | — |
Primary
| Measure | Time frame |
|---|---|
| The incidence of thrombotic events within one month after the operation;All-cause mortality within one month after surgery; | — |
Countries
China
Contacts
Public ContactYang Jiaying
West China Hospital, Sichuan University
Outcome results
None listed